The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines
Open Access
- 1 August 2016
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 78 (3) , 611-622
Abstract
Introduction A number of leptin receptor antagonists have been synthesised for therapeutic use, with pre-clinical tests suggesting their future use in anticancer therapy. To our knowledge, there are no data concerning the possible application of leptin receptor blockers in ovarian cancer. Methods In this study, we evaluated two leptin receptor antagonists: superactive human leptin antagonist (SHLA) and quadruple leptin mutein, Lan-2 (L39A/D40A/F41A/I42A), on cell proliferation (Alamar Blue test, BrdU assay), cell cycle gene (qPCR) and protein expression (Western blot) and cell signalling pathways (Western blot) in three different types of cell lines: OVCAR-3, CaOV-3 and HOSEpiC. Results Both receptor blockers had no effect on non-cancerous HOSEpiC cell line proliferation; however, both reversed the stimulatory effect of leptin on CaOV-3 cell line proliferation to control levels and to below control levels in OVCAR-3 cells. In metastatic carcinoma CaOV-3, both ObR antagonists had an inhibitory effect on the cdk2/cyclin D1 complex, while in serous carcinoma, OVCAR-3, they only had an effect on cdk2 and cdk4 protein expression. SHLA had an inhibitory effect on all investigated signalling pathways in OVCAR-3, while only on Stat3 in CaOV-3. Lan-2 had an inhibitory effect on Stat3 and ERK1/2 in CaOV-3, while in OVCAR-3 it only affected Akt protein phosphorylation. Conclusion Based on these results, we conclude that SHLA and Lan-2 are promising leptin receptor inhibitors which could be used to block leptin activity, eliminating its negative effects on activities related to carcinogenesis. However, the selection of a specific antagonist should be related to tumour type.Keywords
This publication has 40 references indexed in Scilit:
- A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivoJournal of Cellular and Molecular Medicine, 2015
- Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancerEuropean Journal of Cancer, 2011
- Leptin signaling and apoptotic effects in human prostate cancer cell linesThe Prostate, 2010
- Leptin, Soluble Leptin Receptors, Free Leptin Index, and Their Relationship with Insulin Resistance and BMI: High Normal BMI is the Threshold for Serum Leptin Increase in HumansHormone and Metabolic Research, 2010
- Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer CellsCancer Research, 2009
- Leptin modulates the expression of its receptors in the hypothalamic–pituitary–ovarian axis in a differential wayJournal of Endocrinology, 2008
- Significance of E2F-1 overexpression in epithelial ovarian cancerInternational Journal of Gynecological Cancer, 2008
- Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1Breast Cancer Research and Treatment, 2006
- Prostate cancer cell proliferation is influenced by leptin1Journal of Surgical Research, 2004
- Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistanceEuropean Journal of Endocrinology, 2003